Edap Tms (NASDAQ:EDAP) Issues Earnings Results, Misses Expectations By $0.10 EPS

Edap Tms (NASDAQ:EDAP) posted its quarterly earnings results on Wednesday. The medical equipment provider reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.10), FiscalAI reports. The business had revenue of $22.22 million during the quarter, compared to analyst estimates of $21.28 million. Edap Tms had a negative return on equity of 61.60% and a negative net margin of 30.95%.

Edap Tms Stock Performance

Edap Tms stock opened at $3.91 on Wednesday. Edap Tms has a fifty-two week low of $1.21 and a fifty-two week high of $5.05. The firm’s 50 day simple moving average is $4.23 and its 200-day simple moving average is $3.14. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.41 and a quick ratio of 0.97. The company has a market cap of $146.19 million, a P/E ratio of -6.86 and a beta of -0.19.

Hedge Funds Weigh In On Edap Tms

A hedge fund recently bought a new stake in Edap Tms stock. Kovack Advisors Inc. acquired a new position in shares of Edap Tms S.A. (NASDAQ:EDAP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 16,000 shares of the medical equipment provider’s stock, valued at approximately $53,000. 62.74% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on EDAP. Wall Street Zen raised Edap Tms to a “hold” rating in a research note on Saturday, February 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edap Tms in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.50.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.